David Mulholland, MD
Cardiovascular Disease · Jackson, MSNPI 1578509501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 626 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,556, 2.5 times the $1,021 reported in 2019.
Across 626 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Novartis$1K
- Boehringer Ingelheim$990
- Merck$924
- Amgen$879
- AstraZeneca$651
- plus $4K from 29 others
What the payments were for
- Food & beverage$10,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 109 | $1,749 |
| Novartis | 87 | $1,439 |
| Boehringer Ingelheim | 59 | $990 |
| Merck | 46 | $924 |
| Amgen | 64 | $879 |
| AstraZeneca | 31 | $651 |
| Boston Scientific | 35 | $493 |
| Esperion Therapeutics, Inc. | 27 | $467 |
| E.r. Squibb & Sons, L.L.C. | 23 | $396 |
| Pfizer | 23 | $390 |
| Scpharmaceuticals Inc. | 21 | $357 |
| Novo Nordisk | 15 | $286 |
| Alnylam Pharmaceuticals Inc. | 13 | $215 |
| Lexicon Pharmaceuticals, Inc. | 10 | $182 |
| Bayer | 8 | $171 |
| Chiesi USA, Inc. | 9 | $147 |
| Bridgebio Pharma, Inc. | 5 | $112 |
| Kowa Pharmaceuticals America, Inc. | 7 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Abbott | 2 | $49 |
| Abiomed | 2 | $48 |
| Atricure, Inc. | 2 | $46 |
| Medtronic | 1 | $44 |
| Cvrx, Inc. | 2 | $40 |
| Philips North America LLC | 2 | $37 |
| Gilead | 3 | $36 |
| GSK | 1 | $26 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,575 in reported general payments places this provider in the 75th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 782 | $596,489 |
| XareltoRivaroxaban | 318 | $269,472 |
| EntrestoSacubitril/Valsartan | 290 | $229,349 |
| Repatha SureclickEvolocumab | 78 | $58,454 |
| JardianceEmpagliflozin | 63 | $54,654 |
| FarxigaDapagliflozin Propanediol | 41 | $30,822 |
| BrilintaTicagrelor | 61 | $27,838 |
| Praluent PenAlirocumab | 17 | $11,965 |
| Propafenone Hcl ErPropafenone Hcl | 62 | $11,359 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 52 | $11,189 |
| MultaqDronedarone Hcl | 12 | $9,693 |
| Amiodarone Hcl | 183 | $4,605 |
| Metoprolol Succinate | 395 | $4,297 |
| Flecainide Acetate | 129 | $3,979 |
| Rosuvastatin Calcium | 251 | $3,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $390 | $596,489782 claims |
| Johnson & JohnsonXarelto | $1,749 | $269,472318 claims |
| NovartisEntresto | $1,439 | $229,349290 claims |
| AstraZenecaFarxiga, Brilinta | $651 | $58,660102 claims |
| Boehringer IngelheimJardiance | $990 | $54,65463 claims |
| Sanofi-aventis U.S. LLCMultaq | $56 | $9,69312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.